Fractyl Health, Inc. GUTS 深 滬
已收盤 06-05 16:00:00 美东时间
0.6786
-0.055
-7.50%
華盛通- 最 高0.735
- 今 開0.735
- 成交量 294.18万股
- 最 低 0.65
- 昨 收 0.7336
- 總市值 1.08亿
- 52周最高 2.445
- 市盈率 靜 --
- 換手率 1.85%
- 52周最低 0.3772
- 委 比 98.02%
- 總股本 1.59亿
- 歷史最高 14.50
- 量 比 1.84
- 振 幅 11.59%
- 歷史最低 0.3772
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 绩后暴跌，博通仍获11家大行上调目标价；CrowdStrike获21家大行集体上调目标价；Netskope、Veeva Systems惨遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Vivos Therapeutics"买入"评级，目标价从3美元升至3.1美元；富国银行：维持Veeva Systems"超配"评级，目标价从317美元升至320美元
06-05 11:33
Fractyl Health Announces 1-Yr Results From Open-Label REVEAL-1 Cohort; Participants Retained ~78% Of GLP-1 Induced Total Body Weight Loss One Year After Discontinuation And Single Revita Procedure
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure5.3% mean weight change observed with Revita (n=15); published third-party studies after
06-04 19:06
Fractyl Health Q1 2026 Earnings Call: Complete Transcript
Fractyl Health (NASDAQ:GUTS) held its first-quarter earnings conference call on...
05-13 05:26
Fractyl Health Q1 EPS $0.06 Beats $(0.16) Estimate
Fractyl Health (NASDAQ:GUTS) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.16) by 137.5 percent. This is a 112.24 percent increase over losses of $(0.49) per share from
05-13 04:13
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
Fractyl Health Receives Clinical Trial Application Authorization In Netherlands To Initiate Phase 1/2 First-in-human Study Of RJVA-001, Expects To Start Dosing And Report Preliminary Data In 2H of 2026
Authorization advances Fractyl Health to a dual clinical-stage company, with Revita in pivotal development for post-GLP-1 weight maintenance and Rejuva entering first-in-human studies for type 2 diabetesFirst-in-human
05-11 19:06
美股大行评级 | 潜在涨幅33%！大小摩等9家大行上调英特尔目标价；Popular、都福集团、联合太平洋、联合租赁等获多家大行上调评级
今日重点评级关注：瑞银：维持SS&C科技"买入"评级，目标价从112美元升至115美元；Piper Sandler：维持儒博实业"超配"评级，目标价从530美元升至540美元
04-27 14:04
HC Wainwright & Co. Reiterates Buy on Fractyl Health, Maintains $8 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Fractyl Health (NASDAQ:GUTS) with a Buy and maintains $8 price target.
04-24 18:37
Scalable Biotech Manufacturing Unlocks a $14B Market
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflecti...
03-27 21:15
Fractyl Health (GUTS) Stock Jumps 21% After Hours: Here's What You Should Know
Fractyl Health's shares jumped 20.9% after hours following its Q4 2025 results and new weight-maintenance data from the REMAIN-1 Midpoint Cohort.
03-25 14:56
